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Abstract 
Hypermobile Ehlers Danlos Syndrome (hEDS) is a multifaceted disorder that is difficult to 
diagnose and manage primarily due to the unknown causes. Research on hEDS continues 
to evolve but tangible progress will be realized when the growing body of evidence 
compliments clinical practice.  This critical review of the literature aims to stimulate lateral 
thinking about the pathogenesis, diagnosis and management of hEDS. The current 
international classification of Ehlers Danlos Syndrome introduced stricter diagnostic criteria 
for hEDS, which bore a blanket category (hypermobility spectrum disorders) for conditions 
presenting with symptomatic joint hypermobility, but do not match the hEDS diagnostic 
criteria. One would argue hEDS is another all-encompassing classification for heritable 
connective tissue disorders and or acquired musculoskeletal conditions without a definitive 
molecular basis. As scientific research progresses to accommodate validated and or 
annulled hypotheses, the plethora of unknowns in hEDS continue to challenge healthcare 
outcomes and care experiences.  
 
Keywords Hypermobile Ehlers Danlos Syndrome, joint hypermobility, connective tissue 
disorder, diagnosis, management 
 
Introduction  
Ehlers Danlos Syndrome is the overarching term for a range of heritable connective tissue 
disorders, deriving its designation from dermatologists Edvard Ehlers and Henri-Alexandre 
Danlos (Beighton & Beighton, 1986). The updated international classification of Ehlers 
Danlos Syndromes (Malfait et al., 2017) distinguishes 13 subtypes, but this paper focuses on 
hypermobile Ehlers Danlos Syndrome (hEDS) that manifests as a multifactorial condition.  
Malfait et al. (2017) underscored the “dire need for a better clinical definition of the 
hypermobile type of EDS and its delineation from other hypermobility disorders” (p. 9). 
However, authors did not disclose the conflict of interest surrounding the consensus to 
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absorb joint hypermobility syndrome into Ehlers Danlos Syndrome hypermobility type as a 
phenotypic entity with neither consistent evidence nor patient involvement. Patients’ Support 
Groups funded and organized the international symposium held in New York in 2016, where 
the Consortium reached a consensus based on existing literature and the group’s 
professional experience (Bloom et al., 2017). Edvard Ehlers and Henri-Alexandre Danlos 
involved real cases at different fora of EDS debates to affirm precision when based on 
clinical observations (Beighton & Beighton, 1986).  
Presumed to be a heritable disorder of connective tissue, diagnostic criteria for hEDS are 
based on clinical characteristics (Malfait et al., 2017), which present unprecedented 
challenges for subjective interpretations. Benefits from treatment are predictive without 
sound benchmarks and limited understanding of the condition leads to gratuitous 
investigations, wrong therapies and inappropriate referrals (Castori & Voermans, 2014). 
Hypotheses in research initiate further work to annul or qualify thoughts, but the last two 
decades of joint hypermobility research have witnessed numerous theoretical propositions 
without ensuing studies to support assumptions made (Kumar & Lenert, 2017). The growing 
body of research evidence presents a plethora of unknowns, raising questions about what 
hEDS constitutes.  
One of Edvard Ehlers’s professional tenets was undertaking in-depth investigations to 
demarcate symptoms, classify, mark and define disorders based on cause(s) instead of 
coining illnesses as rare or isolated cases and thus under recognized (Beighton & Beighton, 
1986). Several scholars have followed suit to discern hEDS but speculations, inconclusive 
results and emphases of unknowns embody the literature about its pathogenesis and 
etiology (Tinkle et al., 2017). Classified as a heritable connective tissue disorder (HCTD), 
there are no biomarkers to substantiate this presumption following an overall lack of 
reproducible classification of any pathogenic variant in any gene despite using next 
generation sequencing (Forghani, 2019; Syx et al., 2015). Familial diagnoses present 
distinct manifestations within and between families (Castori et al., 2014; Colombi et al., 
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2015). This negatively affects how evidence is embedded in clinical practice to improve 
health outcomes and care experiences. As scientific research on hEDS continues to evolve, 
actual progress will be realized when the evidence compliments clinical practice. This critical 
review of the literature aims to stimulate lateral thinking about the pathogenesis, diagnosis 
and management of hEDS.  
 
Pathogenesis of hEDS 
Like other HCTDs, hEDS is characterized by connective tissue laxity and fragility that 
heighten predisposition to tissue ruptures due to weak tensile loading causing injuries. The 
sequela is contingent on defects in gene expression and the gravity of the mutation in the 
extracellular matrix (Kazkaz & Grahame, 2018), which are unknown for the case of hEDS.   
Prior to amalgamating joint hypermobility syndrome (JHS) and hEDS as one clinical 
condition (Malfait et al., 2017), debates dwelt on whether JHS and hEDS were distinct 
conditions with overlapping characteristics but a similar genetic defect base (De Paepe & 
Malfait, 2012; Castori et al., 2010; Castori & Colombi, 201).  Although gene-environmental 
interaction have not been fully explored in hEDS, Tinkle and colleagues (2009) suggested 
the blurred distinction between hEDS and JHS was due to clinical evolution stimulated by 
age or environmental activity.  Not far from this intimation, Castori et al. (2011) identified a 
sex influence on how hEDS manifests, presuming higher incidence among females than 
males. Castori et al. (2011) recruited a convenient sample of six (n=6) males and forty-four 
(n=44) females to compare symptom prevalence across sexes. Indeed, the majority of 
primary research published constitutes samples of more females than males (Tinkle et al., 
2017). This trend has led to the assumption that a female fetus is more susceptible to a 
genetic predisposition to hEDS (Castori, 2012), which contravenes with distinguishing hEDS 
as an autosomal dominant trait. For undefined reasons, a female conceptus is deemed more 
likely to develop hEDS than a male conceptus.   On the other hand, evidence supporting 
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hEDS as an autosomal dominant trait is debatable due to inconsistences registered in the 
hypermobility assessment tools used (Castor & Colombi, 2015). Questions henceforth arise 
relating to what constitutes hEDS. 
Researching the impact of sex on health transcends the occurrence or absence of a Y 
chromosome to discern biological, physiological and social aspects and their effects 
(Institute of Medicine, 2006). Whilst the literature briefly cites a reproductive perspective 
(Castori, 2012; 2013), I have not come across research investigating the role of the 
reproductive system in the pathophysiology of hEDS. For example, testosterone has positive 
effects on sensory awareness of pain (Vincent & Tracey, 2008) and disproportionate levels 
of testosterone in sexes could modulate health seeking behaviors amongst people 
diagnosed with hEDS.  The fluctuation of hormone serum range for controlling immune and 
inflammatory functions during late luteal and or menses in females may equally have an 
impact on symptomatology and clinical evolution of hEDS.  
Although heterogeneous in presentation, gastrointestinal involvement is highly common in 
hEDS (Castori & Grammatico, 2015). Compelling evidence identifies the role of sex 
hormones in modulating the brain gut axis resulting symptomatic disorders such as migraine 
headaches, chronic pelvic pain and fatigue (Mulak et al., 2014; Heitkemper & Jarrett, 2008), 
which are more common in females than males (Castori et al., 2010).  Similarly, substantial 
evidence exists about the influence of sex differences in innate immunity to conditions 
associated with chronic pain and pain experience (Castoriet al., 2010a; Sorge & …2.018), 
An introduction of testosterone  in female mice facilitated use of microglia in the spinal cord 
to mediate chronic pain like the male mice instead of T cells (Sorget et al., 2015).  
Testosterone is known for its anti-nociceptive functions ((Bartley & Fillingim, 2016; Craft, 
2007), which explains the effects of the lower levels of androgens in the female sex on the 
threshold for sensory awareness of pain (Bartley & Fillingim, 2013; Carins & Gazerani, 
2009).  Thus, deductions about female fetuses being more receptive to a mutated gene than 
their male counterparts require better empirical evidence than a headcount of service users 
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in hypermobility clinics.  The hEDS research community is yet to witness research following 
systematic and non-sex biased sample recruitment to offer a balanced reflection of 
characteristics and factors that underpin variances in clinical expression.  
 
Diagnosing hEDS 
Delayed diagnoses are resource intensive due to multiple healthcare consultancies and 
erroneous therapies (Castori, 2012). The introduction of stricter diagnostic criteria for hEDS 
(Malfait et al., 2017) is marginally helpful since diagnostic accuracy using clinical definitions 
is still contingent on physicians’ experience of undertaking similar assessments. Evidence of 
a plausible relationship between the mutation of Tenascin XB and hEDS (Petersen & 
Douglas, 2013) is currently untenable because the statistical correlation in the originating 
study was not significant (Zeweers et al., 2005).   Besides, traditional statistical modelling 
does little to detect complex genetic and environmental structures of multifaceted conditions 
(Institute of Medicine, 2006). In the same vein, a few people diagnosed with hEDS and a 
definitive genetic mutation on Tenascin XB have illustrated symptoms similar to classical 
EDS (Kaufman & Butler, 2016).  The sole focus on isolating Mendelian patterns without 
exploring the impact of environmental influences on how hEDS manifests may deter useful 
results in deciphering the multifactorial condition.  
The updated classification of EDS includes flexible cut off points on the Beighton score to 
compensate for changes in joint movement in hEDS (Malfait et al., 2017). However, the 
stricter diagnostic framework does not incorporate means of controlling for implicit nor 
explicit influences on joint movement and hence leaving room for diagnostic error.  The 
stricter diagnostic criteria for hEDS gave rise to a blanket category (hypermobility spectrum 
disorders [HSDs]) for conditions presenting with symptomatic joint hypermobility, but not 
matching the hEDS diagnostic criteria (Castori et al., 2017; Castori & Hakim, 2017). One 
would also argue that hEDS is an all-encompassing category for progressive heritable 
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connective tissue disorders and or acquired musculoskeletal conditions without a molecular 
basis. Aggregate propositions in the literature blur certitude about the heritable nature of 
hEDS and its pathophysiology. For example, the HSDs category is an exclusionary 
diagnosis for hEDS, but HSDs are likely to revert to asymptomatic joint hypermobility or 
mutate to hEDS (Castori & Hakim, 2017). Moreover, generalized hypermobility, a 
characteristic that must be met for an accurate diagnosis of hEDS is typically congenital but 
can also be acquired (Castori et al., 2017). While such prepositions may not be entirely 
inaccurate, it would help to distinguish unique numerators for acquired or heritable joint 
hypermobility to qualify the supposed syndromic temperament of hEDS.  
Some researchers present hEDS as a metamorphosis of joint hypermobility underpinned by 
variable expression at different life stages (Castori & Colombi, 2015; Castori et al., 2017). 
Although hEDS is a presumed heritable connective tissue disorder, it is likely to remain 
passive as asymptomatic joint hypermobility until exposed to activators that are yet to be 
defined (Castori et al., 2017).  
“HSD is not always a permanent diagnosis and may change into asymptomatic joint 
hypermobility in case of complete resolution of symptoms or into hEDS (or, perhaps, other 
genetic disorders)” [Castori & Hakim, 2017 p.645]. Figure 1 is one interpretation of Castori and 
Colombi (2015) and Castori et al. (2017) rationalization of the development of hEDS along the 
joint hypermobility spectrum.  
Figure 1 Evolution of hEDS along the joint hypermobility spectrum 
[Figure 1]  
adapted from the hierarchical stratification of joint hypermobility. (Castori, M. and Colombi, M., 
2015. Generalized joint hypermobility, joint hypermobility syndrome and Ehlers‐Danlos 
syndrome, hypermobility type. Am. J. Med. Genet. Part C Sem Med. Genet. 169(1), pp. 1-5) 
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Stratifying joint hypermobility in a hierarchical order (Castori & Colombi, 2015) illustrates 
clinical evolution to other undetermined HCTDs at the highest level of the hierarchy.  This 
implies a hEDS diagnosis is not conclusive until clarity about a yet undiscovered, defective 
gene(s) is obtained or not. Until then, the joint hypermobility research community oscillates in 
knots of uncertainties.  
Symptoms in hEDS 
Hypermobile Ehlers Danlos Syndrome is multifaceted in clinical presentation with a range of 
symptoms that can hardly be generalized (Scheper et at., 2015). The discussion here is not 
exhaustive but rather highlights a few examples of inconclusive areas in the literature. A 
wide spectrum of neurological, mucocutaneous, musculoskeletal and gastrointestinal 
complaints present uniquely in hEDS. For example, a study of clinical heterogeneity of hEDS 
observed common musculoskeletal complaints but widespread non-musculoskeletal clinical 
disparity attributing this to genetic variability or dysautonomia (De Wandele et al., 2013). 
Prepositions for clinical heterogeneity followed genetic relations without illuminating the role 
of environmental risk factors. A follow-on study established dysautonomia in hEDS 
highlighting peripheral sympathetic neuropathy and medication with autonomic side effects 
as likely causes for dysautonomia (De Wandele et al., 2014).  The commonest types of 
dysautonomia in hEDS are thought to be neurocardiogenic syncope and postural orthostatic 
tachycardia syndrome (Tinkle et al., 2017). However, muscle weakness, a trait prevalent in 
hEDS is primarily found in familial dysautonomia with a known mutation of the IKBKAP/ 
ELP1 gene (Axelrod, 2004).  
Muscle weakness, proprioception and physical activity in hEDS are not sufficiently 
understood perhaps due to cross-sectional and statistical methods used in discerning clinical 
evolution happening in female adults over time. For example, Scheper et al. (2017) reported 
inconsistent results from a cross sectional study of the influence of proprioception on muscle 
strength and activity limitations. Muscle weakness and poor resistance affect movement and 
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posture but the lack of strength in the muscles is due to anomalies instead of muscle waste 
(Proske & Gandevia, 2012). A statistical control for physical activity in a study examining 
lower extremity muscle mass, muscle strength, functional performance and physical 
impairment still indicated very low muscle strength in hEDS attributed to abnormalities in the 
muscle extracellular matrix (Rombaut et al., 2012). Nonetheless there is continued  
Causes of severe pain predominant in hEDS present another area of contention (Voermans 
et al., 2010; Scheper et al., 2015). Agreement about pain activation is more around joint 
hypermobility and dislocations particularly of the knees, ankles and shoulders but peripheral 
neuropathy, muscle cramps and tendinitis add to propositions for pain triggers (Rombaut et 
al., 2010). Whist pain in most conditions related to joint hypermobility could be as a result of 
trauma from excess joint movement, it is anticipated that the pain is independent of causes 
of the initial joint condition (Castori et al., 2013; Scheper et al., 2017) The complexity of 
understanding pain and its severity emanates from an interplay of various malfunctions 
within and around a diagnosis of hEDS (Scheper et al., 2015).  
Hypermobile Ehlers Danlos Syndrome is largely corelated with psychiatric disorders (Baeza-
Velasco et al., 2015; Cederlöf et al., 2016) but descriptions of their triggers are weakly 
founded. For example, Pasquini et al. (2014) linked the high risk and prevalence of 
obsessive-compulsive disorder in hEDS with controlling parents. Whilst genes plus gene-
environment interactions may influence personality (Moffit et al., 2006), the causal factor 
here is too constricted to explicate biochemical chains and how these could be delineated 
from environmental influences in context of a presumed autosomal dominant disorder.  It is 
not clear whether the resultant psychiatric disorder is a response of gene expression to the 
controlling environment or whether the controlling trait follows genetic determinism.   
Pasquini et al. (2014) also associated perfectionism to healthcare professionals’ lack of 
understanding of hEDS, which is a reductionist view to feelings of frustration, humiliation and 
resentment resulting from shortcomings in practitioners’ person-centered practice (Berglund 
et al., 2010; Knight, 2015). Bulbena et al. (2017) posit a possible role of dysautonomia and 
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fatigue on mental wellbeing in hEDS, which can easily be misdiagnosed as psychiatric 
disorders such as anxiety, depression and panic attacks. Although not all genetic outcomes 
are obtained through the environment, exploring measured gene-environment interactions is 
useful in understanding complex health conditions (Moffit et al., 2006).    
 
Managing hEDS 
Hypermobile Ehlers Danlos Syndrome is characteristically a systemic condition that causes 
complex and lengthy experiences specifically in the management of pain and fatigue 
affecting individuals’ quality of life (Knight, 2015).  Inadequate effect of drug treatment and 
poorly controlled medication or physical therapy exemplify practice in managing hEDS 
(Castori et al., 2014).  Evidence of causes of severe pain is inconclusive and the challenges 
for physicians are overwhelming since usual pain relief measures are often ineffective 
(Chopra et al., 2017). Castori et al. (2013) contend both central and peripheral elements 
intrinsically underpin pain sensation in hEDS, but assessing and managing a subjective 
experience effectively is contentious without clear guidance.  Pharmacology attests to high 
doses of opioids for pain management outside of clinical guidance to alleviate human 
suffering (Tennant, 2014). The highly recommended interdisciplinary management is 
beneficial to both physicians and patients (Castori et al., 2015; Bathen et al., 2013), but this 
is difficult to attain in fragmented systems of healthcare that people with rare conditions 
struggle to navigate (Simpson, 2016). Cherry- picking from existing pain control measures to 
suit individual needs (Castori et al., 2012) flags numerous uncontrolled trials, failing to 
benchmark and build on what works to improve healthcare outcomes. A humanization 
framework is a practical guide in enabling experiential understanding of individuals and their 
condition (Clark & Knight, 2017) however, short appointments and performance driven 
healthcare systems restrict deep involvement in care processes.  
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Conclusion  
As scientific research develops to accommodate validated and or annulled hypotheses, the 
plethora of unknowns in hEDS continue to challenge healthcare outcomes and experiences 
of care.  The literature about hypermobile Ehlers Danlos Syndrome is crowded with 
uncertainties and thus condition management is mostly predictive. Molecular mechanisms 
involvement has become a quick and safe way to explain unclear domains in hEDS despite 
the lack of biomarkers to date. The hierarchical stratification of joint hypermobility implies 
people diagnosed with hEDS are yet to receive another diagnosis. The task for future 
research is to explore environmental influences and control for anatomical variations in 
phenomenon examined, particularly if sex is a contributing factor.  
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